KMDA: צמיחה צפויה ברווח למניה לשנה הבאה kamada.com
Despite pressure from global players and raw material shortage risks, stringent FDA requirements and patent protection create an insurmountable barrier for new entrants. The consensus forward EPS growth forecast helps balance these factors, where the value of 19.50 corresponds to the current metric. Consequently, Kamada Ltd. (KMDA) maintains its leadership in the B2B rare disease segment thanks to unique antibodies.
פילוחים אנליטיים ודוחות נתונים של חברת kamada.com (KMDA)
The resilience of Kamada Ltd. (KMDA) is based on the non-cyclical demand for plasma-derived therapies and the stability of government contracts. This metric aggregates expert consensus forecasts for earnings per share (EPS) changes, reflecting market yield expectations. By analyzing the current valuation of the company's EPS growth for the coming year, an investor determines the probability of earnings deviating from the norm. These data allow for the adjustment of the asset's fair value based on future cash flows.
